Human atrial natriuretic peptide during perioperative period for completely resected non-small cell lung cancer: a multicentre, open-label, randomised controlled trial

Human atrial natriuretic peptide during perioperative period for completely resected non-small cell lung cancer: a multicentre, open-label, randomised controlled trial - Japan Human Atrial Natriuretic Peptide for Lung Cancer Surgery (JANP study)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018480

Enrollment

500

Registered

2015-07-31

Start date

2015-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

A: Lung cancer surgery with hANP treatment [Patients in the hANP group receive human ANP (0.025 microgram/kg/min for 3 days), which is started more than two hours before surgery] B: Surgery alone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Preoperative criteria 1. Non-small cell lung cancer is suspected. 2. Thin-section CT fulfills the proportion of maximum diameter of the tumor itself to consolidation is more than 0.25. 3. It's possible to perfom the complete resection including mediastinal lymph node dissection. 4. Patient without simultaneous or metachronous (within the past 5 years) double cancers. 5. Aged more than 20 years 6. Performance status of 0-2. 7. Sufficient organ functions. 8. All patients gave written informed consent

Exclusion criteria

Exclusion criteria: 1. Thin-section CT fulfills the proportion of maximum diameter of the tumor itself to consolidation is less than 0.25. 2. Patient with active the other concurrent malignant diseases. 3. Women during pregnancy or breast-feeding. 4. Psychosis. 5. Systemic steroids or immunosuppressive agents medication. 6. Uncontrollable infectious disease, autoimmune disease, or the other severe comorbidities. 7. History of right ventricular infarction. 8. Severe hypotension 9. Other conditions judged ineligible by physician

Design outcomes

Primary

Measure	Time frame
Two-year relapse free survival after lung cancer surgery	—

Secondary

Measure	Time frame
1. five-year relapse free survival after lung cancer surgery 2. Over all survival (5 years after surgery) 3. The ratio of the patients who completed the treatment 4. The incidence of postoperative complications	—

Countries

Japan

Contacts

Public ContactTakashi Nojiri

National Cerebral and Cardiovascular Center Research Institute/Osaka University Hospital Biochemistry/General Thoracic Surgery

nojiri@ri.ncvc.go.jp06-6833-5012

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026